Posts Tagged ‘Teresa Gallart’

Wednesday January 02nd, 2013

A therapeutic dendritic cell vaccine for HIV-1 infection controls virus replication temporarily

Combination antiretroviral therapy (cART) is a success of modern medicine that greatly improves survival and quality of life of HIV-1–infected patients. The major drawback is that cART must be maintained indefinitely causing inconveniences to patients, potential long term toxicities and carrying elevated economical cost. Research teams across the globe work to find an alternative to “cART for life”, such as inducing HIV-1–specific immune responses to control viral replication after discontinuation of cART. Investigators from the AIDS and Infectious Diseases team of the Hospital Clínic/IDIBAPS at University of Barcelona, led by Dr. Josep Maria Gatell, report today in Science Translational Medicine the safety, tolerability, immunogenicity and virologic response results obtained with a new therapeutic vaccine candidate.


Watch it on Youtube in English.

Read the rest of this entry »

Comments Closed
Tuesday February 01st, 2011

Therapeutic AIDS vaccine designed by the HIVACAT reduces the viral load in the majority of AIDS patients

Therapeutic AIDS vaccine designed by the HIVACAT

The therapeutic vaccines are a priority research line of the HIVACAT, the catalan programme for the development of therapeutic vaccines and prevention against the Human Immunodeficiency Virus (HIV). This type of therapeutic vaccine helps the patients who are carriers of the virus, combat infection and control the appearance of AIDS in the same way as with the current antiretroviral treatments.  The final aim of the therapeutic vaccines will be to avoid a life long treatment with antiretroviral drugs.  The research team ‘Infectious Diseases and AIDS’ led by Dr. Josep Maria Gatell from IDIBAPS – Hospital Clínic   has developed using the brand HIVACAT, a model of the therapuetic vaccine based on the patient’s own  dendritic cells. This reduction in the viral load is still considered to be insuficient but it is the first therapeutic vaccine which has achieved a postive response in the majority of patients.

Read the rest of this entry »

Comments Closed